Genetic Testing & Malignant Hyperthermia Risk: 3-Question Screening

Genetic testing is increasingly recognized as a key tool in identifying individuals at risk of malignant hyperthermia (MH), a rare but potentially fatal reaction to certain anesthetics. New guidance, outlined in an article published online March 10 in Anesthesiology, suggests that a few simple screening questions, coupled with genetic testing, can significantly improve risk assessment for patients undergoing surgery. This development offers a more proactive approach to patient safety, particularly for those with a family history suggestive of the condition.

Understanding Malignant Hyperthermia

Malignant hyperthermia is a pharmacogenetic disorder, meaning it’s triggered by specific drugs in genetically susceptible individuals. Typically, the reaction is brought on by volatile anesthetics – inhaled gases used to induce and maintain anesthesia – and the muscle relaxant succinylcholine. When exposed to these agents, individuals with MH experience a cascade of physiological changes, including dangerously high body temperature, muscle rigidity, and a rapid increase in heart rate, and metabolism. Whereas effective treatments exist, early recognition and intervention are crucial, as MH can be fatal if left unaddressed.

The underlying cause of MH lies in genetic mutations affecting muscle metabolism. These mutations most commonly occur in the RYR1 gene, but can also involve CACNA1S and STAC3, as detailed in research published in Genes in October 2025. These genetic defects disrupt the normal function of calcium regulation within muscle cells, leading to the uncontrolled metabolic response during anesthesia.

A Stepwise Approach to Risk Assessment

Historically, diagnosing MH susceptibility has been challenging. Accurate tests, such as the caffeine-halothane contracture test, are invasive, expensive, and available at only a limited number of specialized centers in North America. The new guidance emphasizes a stepwise approach, beginning with a thorough patient history and family screening. According to Dr. Sheila Riazi of the University Health Network and the University of Toronto, the lead author of the Anesthesiology article, “Identifying patients potentially at risk for MH is a critical priority for anesthesiologists, but challenging to diagnose.”

The guidance suggests that patients with a personal or family history of a suspected MH reaction should be considered for genetic testing. This testing can identify the presence of known MH-causing mutations, providing a more definitive assessment of risk. It’s estimated that the prevalence of MH ranges from 1 in 2,000 to 1 in 3,000, but can be as high as 1 in 800, highlighting the importance of proactive screening.

The Role of Genetic Testing: Benefits and Limitations

The advent of next-generation sequencing (NGS) has revolutionized MH diagnostics, offering a less invasive and more accessible method for identifying susceptible individuals. Though, genetic testing isn’t without its limitations. As noted in the Genes article, incomplete penetrance – where individuals with a known mutation don’t always exhibit symptoms – and the variable pathogenicity of different genetic variants pose challenges. Not all identified mutations are equally likely to cause a reaction, and functional confirmatory testing may be needed to determine the clinical significance of certain variants.

access to comprehensive genetic testing and interpretation of results can be limited by cost and availability. The American Society of Anesthesiologists (ASA) news release highlights the importance of a coordinated approach to genetic testing, ensuring that results are accurately interpreted and used to inform clinical decision-making.

What This Means for Patients

For patients identified as MH-susceptible (MHS), surgery can still be performed safely, but requires careful planning and the use of alternative anesthetic approaches. Total intravenous anesthesia (TIVA), which avoids volatile anesthetics, is a common and effective strategy for MHS patients. The goal is to minimize the risk of triggering an MH reaction while still providing adequate pain control and muscle relaxation during the procedure.

It’s important to emphasize that MH is rare, and the vast majority of patients undergoing anesthesia do not experience any adverse reactions. However, for those with a family history or other risk factors, genetic testing can provide valuable information to help anesthesiologists tailor their approach and ensure patient safety. The Mayo Clinic provides detailed information on diagnosis and treatment of malignant hyperthermia, emphasizing the importance of prompt recognition and management.

Looking Ahead: Ongoing Research and Guidance Updates

The field of MH research is continually evolving. Ongoing studies are focused on identifying new genetic mutations, improving our understanding of the underlying mechanisms of the disease, and developing more effective diagnostic and therapeutic strategies. The ASA and other professional organizations are committed to regularly updating their guidance based on the latest scientific evidence. This includes refining screening protocols, improving access to genetic testing, and developing educational resources for both healthcare professionals and patients.

As genetic testing becomes more widely available and affordable, it is likely to play an even greater role in identifying individuals at risk of MH. This proactive approach will help to minimize the risk of this rare but potentially life-threatening complication, ensuring safer and more effective anesthesia care for all.